Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-01-2009 | Retinal Disorders

Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy

Authors: Shinko Nakamura, Naoko Iwasaki, Hideharu Funatsu, Shigehiko Kitano, Yasuhiko Iwamoto

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 1/2009

Abstract

Background

The development of diabetic retinopathy is associated with the duration of diabetes and HbA1c levels. However, the familial aggregation of diabetic retinopathy is consistent with genetic susceptibility. Recently, a –634C/G polymorphism in the vascular endothelial growth factor (VEGF) gene was shown to be associated with diabetic retinopathy. To clarify the contribution of the VEGF gene in the development of diabetic retinopathy we analyzed variants in this gene among 469 Japanese patients with type 2 diabetes.

Methods

DNA from each patient was typed for –634C/G and –2578C/A polymorphisms using conventional polymerase chain reaction techniques. The vitreous fluid samples were obtained from 40 patients with PDR for measurement of VEGF levels.

Results

We found a significantly higher frequency of the A allele in the group with proliferative diabetic retinopathy (PDR) than in the control group at –2578C/A polymorphism (p = 0.036). Moreover, if the subjects were grouped according to the duration of diabetes and status of diabetic retinopathy (a first group consisting of subjects with longer duration (>20 y) of diabetes without any retinopathy (n = 102), and a second group of those with shorter diabetes (<15 y) but having retinopathy (n = 35), the genotype distribution at -2578 C/A polymorphism was again significantly higher in the second group (p = 0.005) and differed significantly (p = 0.002) in a recessive model. The risk of the AA for PDR was 7.7 (95%, CI: 1.8–30.9).

Conclusions

The AA genotype at –2578C/A polymorphism in the VEGF gene is associated with proliferative diabetic retinopathy. No significant association with –634 C/G polymorphism was confirmed.

The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986. doi:10.1056/NEJM199309303291401 CrossRef

UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853. doi:10.1016/S0140–6736(98)07019–6 CrossRef

Cai J, Boulton M (2002) The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye 16:242–260. doi:10.1038/sj.eye.6700133 PubMedCrossRef

Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S (2000) Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab Res Rev 16:393–407. doi:10.1002/1520–7560(0000)9999:9999<::AID-DMRR157>3.0.CO;2-G PubMedCrossRef

Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611. doi:10.1210/er.2003–0027 PubMedCrossRef

Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J (1996) Localization of vascular endothelial growth factor in human retina and choroids. Arch Ophthalmol 114:971–979PubMed

Funatsu H, Yamashita H, Nakanishi Y, Hori S (2002) Angiotensin IIand vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 86:311–315. doi:10.1136/bjo.86.3.311 PubMedCrossRef

Yang B, Cross DF, Ollerenshow M, Millward BA, Demaine AG (2003) Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabet Complications 17:1–6. doi:10.1016/S1056–8727(02)00181–2 CrossRef

Awata T, Inoue I, Kurihara S, Ohkubo T, Watanabe M, Inukai K et al (2002) A common polymorphism in the 5’-untranslated region of the VEGF gene Is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635–1639. doi:10.2337/diabetes.51.5.1635 PubMedCrossRef

10.

Szaflik JP, Kowalski TW, Majsterek I, Borucka AI, Blasiak J, Szaflik J (2007) An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246(1)39–43

11.

Roberto DB, Marina S, Serena G et al (2006) VEGF gene variability and type 1 diabetes: evidence for a protective role. Immunogenetics 58:107–112. doi:10.1007/s00251–006–0089–2 CrossRef

12.

World Health Organ Tech Rep Ser (1985) Diabetes mellitus. Rep WHO Study Group 727:1–113.

13.

Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Chah ST et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1(331):1480–1487. doi:10.1056/NEJM199412013312203 CrossRef

14.

Hyodo I, Doi T, Endo H et al (1998) Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 34:2041–2045. doi:10.1016/S0959–8049(98)00282–2 PubMedCrossRef

15.

Kitamura Y, Moriguchi M, Kaneko H, Morisaki T, Toyama K, Kamatani N (2002) Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using EM algorithm. Ann Hum Genet 66:183–193. doi:10.1046/j.1469–1809.2002.00112.x PubMedCrossRef

16.

Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Siviridis E (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 6:293–298. doi:10.1016/j.lungcan.2004.04.037 CrossRef

17.

Howell WM, Ali SJ, Rose-Zerilli M, Ye S (2005) VEGF polymorphisms and severity of atherosclerosis. J Med Genet 42:485–490. doi:10.1136/jmg.2004.025734 PubMedCrossRef

18.

Del Bo R, Scarlato M, Ghezzi S, Martinelli B, Fenoglio C, Galbaiati S et al (2005) Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol 57:373–380. doi:10.1002/ana.20390 PubMedCrossRef

19.

Szeto CC, Chow KM, Poon P, Szeto CY, Wong TY, Li PK (2004) Genetic polymorphism of VEGF: Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney Int 63:1947–1955. doi:10.1111/j.1523–1755.2004.00605.x CrossRef

20.

Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV et al (2002) Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13:260–264PubMed

21.

Jin Q, Hemminki K, Forsti A et al (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 1:3647–3653. doi:10.1158/1078–0432.CCR-04–1803 CrossRef

22.

Banyasz I, Bokodi G, Vannay A, Szebeni B, Treszl A, Vasarhelyi B, Tulassay T, Szabo A (2006) Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity. Curr Eye Res 31:685–690. doi:10.1080/02713680600801123 PubMedCrossRef

23.

Awata T, Kurihara S, Takata N, Neda T, Iizuka H, Ohkubo T et al (2005) Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macula retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 333:679–685. doi:10.1016/j.bbrc.2005.05.167 PubMedCrossRef

24.

Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P et al (2006) Association of VEGF and eNOS gene polymorphism in type 2 diabetic retinopathy. Mol Vis 12:336–341PubMed

25.

Steto C-C, Chow K-M, Poon P, Steto CY-K, Wong TY-H, Li PK-T (2004) Genetic polymorphism of VEGF: impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney Int 65:1947–1955. doi:10.1111/j.1523–1755.2004.00605.x CrossRef

26.

Burgos R, Simo R, Audi L, Mateo C, Mesa J, Garcia-Ramirez M et al (1997) Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia 40:1107–1109. doi:10.1007/s001250050794 PubMedCrossRef

27.

Aiello LP, Iwamoto MA et al (1995) Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 113:1538–1544PubMed

28.

Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM et al (2003) Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9:210–216PubMed

29.

Tolentino M, Brucker AJ, Fosnot J, Ying GS, Wu IH, Malik G et al (2004) Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24:132–138. doi:10.1097/00006982–200402000–00018 PubMedCrossRef

Title: Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy
Authors: Shinko Nakamura
Naoko Iwasaki
Hideharu Funatsu
Shigehiko Kitano
Yasuhiko Iwamoto
Publication date: 01-01-2009
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 1/2009
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-008-0915-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2009

Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP): 18-month experience with telemedicine screening

Circulatory parameters in the retrobulbar central retinal artery and vein of patients with diabetes and medically treated systemic hypertension

Repeatability intraexaminer and agreement in amplitude of accommodation measurements

Lutein prevents cataract development and progression in diabetic rats

Parafoveal letter recognition at reduced contrast in normal aging and in patients with risk factors for AMD

Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide)